Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Discovery of new potent, selective and orally bioavailable inhibitors of factor XI

Oct. 2, 2020

BCX-9930 shows clinical benefit as monotherapy in treatment-naive patients with PNH

Oct. 1, 2020

Enaroy approved in Japan for anemia associated with chronic kidney disease

Sep. 29, 2020

FDA approves Nucala for hypereosinophilic syndrome

Sep. 28, 2020

Phase I/IIa data published for BIVV-001 in patients with hemophilia A

Sep. 21, 2020

OD-66 restores hemoglobin levels in model of cancer-induced anemia

Sep. 15, 2020

Blood studies identify new trait-related variants

Sep. 10, 2020

Enrollment begins in phase I study of AG-946

Sep. 9, 2020

Midwestern University describes isotopically stabilized tetronimide compounds

Sep. 7, 2020

S-62798 demonstrates efficacy in mouse model of thromboembolism

Sep. 7, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 7, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 7, 2024.
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...
Sanofi bets on Resalis’ oligonucleotide RES-010 for obesity
BioWorld
After missing out on the glucagon-like peptide 1 obesity market, Sanofi SA is prospecting for next-generation drugs and is making a strategic equity investment in...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.